What were Jenburkt Pharmaceuticals Ltd's latest quarterly results?
Jenburkt Pharmaceuticals Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +22.2% (stable)
- Revenue Growth YoY: +9.8%
- Operating Margin: 32.0% (volatile)
Jenburkt Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +10.7%AverageNew This Week
In , Jenburkt Pharmaceuticals Ltd (Pharma - Others) is outperforming Nifty 500 with +10.7% relative strength. Fundamentals: Average.
Jenburkt Pharmaceuticals Ltd Key Facts
- PE Ratio
- 13.6x
- Market Cap
- ₹513 Cr
- PAT Growth YoY
- +22%
- Revenue Growth YoY
- +10%
- OPM
- 32.0%
- RS vs Nifty 500
- +10.7%
PE: Early ExpansionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
💪Debt reduced 50% YoY — balance sheet strengthening
Key Numbers
PAT Growth YoY
+22%
Stable
Revenue YoY
+10%
Stable
Operating Margin
32.0%
+600 bps YoY
PE Ratio
13.6
Current Price
₹1,163
Dividend Yield
1.55%
Fundamental Score
57/100
Average
3Y PAT CAGR
+12%
Market Cap
513 Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Jenburkt Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +10% | +7% | Stable |
| PAT (Net Profit) | +22% | +12% | Stable |
| OPM | 32.0% | +600 bps | Volatile |
Other Top Pharma - Others Stocks Beating Nifty 500
Frequently Asked Questions: Jenburkt Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Jenburkt Pharmaceuticals Ltd's profit growing or declining?
Jenburkt Pharmaceuticals Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +22.2% (latest quarter)
- PAT Growth QoQ: +83.3% (sequential)
- 3-Year PAT CAGR: +11.9%
- Trend: Stable — consistent growth pattern
What is Jenburkt Pharmaceuticals Ltd's revenue growth trend?
Jenburkt Pharmaceuticals Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +9.8%
- Revenue Growth QoQ: +4.7% (sequential)
- 3-Year Revenue CAGR: +7.3%
How is Jenburkt Pharmaceuticals Ltd's operating margin trending?
Jenburkt Pharmaceuticals Ltd's operating margin is volatile.
- Current OPM: 32.0%
- OPM Change YoY: +6.0% basis points
- OPM Change QoQ: +15.0% basis points
What is Jenburkt Pharmaceuticals Ltd's 3-year profit and revenue CAGR?
Jenburkt Pharmaceuticals Ltd's long-term compounding rates
- 3-Year Profit CAGR: +11.9%
- 3-Year Revenue CAGR: +7.3%
Is Jenburkt Pharmaceuticals Ltd's growth accelerating or decelerating?
Jenburkt Pharmaceuticals Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: +36.5% bps
- Sequential Acceleration: +90.0% bps
What is Jenburkt Pharmaceuticals Ltd's trailing twelve month (TTM) performance?
Jenburkt Pharmaceuticals Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹35 Cr
- TTM PAT Growth: +6.1% YoY
- TTM Revenue: ₹170 Cr
- TTM Revenue Growth: +11.8% YoY
- TTM Operating Margin: 25.9%
What is Jenburkt Pharmaceuticals Ltd's current PE ratio?
Jenburkt Pharmaceuticals Ltd's current PE ratio is 13.6x.
- Current PE: 13.6x
- Market Cap: 513 Cr
- Dividend Yield: 1.55%
What is Jenburkt Pharmaceuticals Ltd's price-to-book ratio?
Jenburkt Pharmaceuticals Ltd's price-to-book ratio is 2.6x.
- Price-to-Book (P/B): 2.6x
- Book Value per Share: ₹446
- Current Price: ₹1163
Is Jenburkt Pharmaceuticals Ltd a fundamentally strong company?
Jenburkt Pharmaceuticals Ltd is rated Average with a fundamental score of 56.5/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +9.8% (10% weight)
- PAT Growth YoY: +22.2% (10% weight)
- PAT Growth QoQ: +83.3% (10% weight)
- Margins stable (10% weight)
Is Jenburkt Pharmaceuticals Ltd debt free?
Jenburkt Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹2 Cr
What is Jenburkt Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Jenburkt Pharmaceuticals Ltd's return ratios over recent years
- FY2024: ROCE 26.0%
- FY2025: ROCE 27.0%
- FY2026: ROCE 27.0%
Is Jenburkt Pharmaceuticals Ltd's cash flow positive?
Jenburkt Pharmaceuticals Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹27 Cr
- Free Cash Flow (FCF): ₹8 Cr
- CFO/PAT Ratio: 77% (adequate)
What is Jenburkt Pharmaceuticals Ltd's dividend yield?
Jenburkt Pharmaceuticals Ltd's current dividend yield is 1.55%.
- Dividend Yield: 1.55%
- Current Price: ₹1163
Who holds Jenburkt Pharmaceuticals Ltd shares — promoters, FII, DII?
Jenburkt Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 46.6%
- FII (Foreign): 0.0%
- DII (Domestic): 0.1%
- Public: 53.2%
Is promoter holding increasing or decreasing in Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 46.6% (Mar 2026)
- Previous Quarter: 46.6% (Dec 2025)
- Change: -0.01% (decreasing — worth monitoring)
How long has Jenburkt Pharmaceuticals Ltd been outperforming Nifty 500?
Jenburkt Pharmaceuticals Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Jenburkt Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Jenburkt Pharmaceuticals Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Jenburkt Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Jenburkt Pharmaceuticals Ltd may be worth studying
- Earnings growing at +22.2% YoY
- Cash flow is positive — CFO ₹27 Cr
What is the investment thesis for Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd investment thesis summary:
What is the future outlook for Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.